Novo Nordisk's Stock Drops Significantly

Novo Nordisk experienced a notable decline in its shares on Friday, dropping more than 2% following the publication of a preprint study on medRxiv that suggested a potential link between Ozempic and a rare vision condition.

Study Details and Findings

The study, conducted by a team of scholars from Norway and Denmark, indicated that diabetes patients who used Ozempic were more than twice as likely to be diagnosed with NAION, a rare vision condition. This revelation has raised concerns among investors and the medical community alike.

Market Reaction

By 11:15 am ET, Novo Nordisk's shares had fallen by 2.49%, trading at $105.86. This substantial drop in share value underscores the market's sensitivity to potential safety issues related to the company's products.